Inactive Instrument

Company GENFIT Euronext Paris

Stocks

FR0004163111

Biotechnology & Medical Research

End-of-day quote Euronext Paris
- ^EUR	-

07-03	Genfit soars on news of U.S. reimbursement for a product
07-03	Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement	MT

Business description: GENFIT

GENFIT is a biopharmaceutical company in late-stage development focused on the discovery and development of innovative therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, in particular due to a lack of approved treatments. GENFIT is a leading innovator in the field of nuclear receptor-based drug discovery with a rich history and a solid scientific heritage spanning nearly two decades.

The company has offices in Lille, Paris, Zurich and Cambridge, MA (USA).

Sales by Activity: GENFIT

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
Research and Development of Innovative Medicines and Diagnostic Solutions	85.36M	26.25M	34.48M	70.69M	70.84M

See all business segments

Geographical breakdown of sales: GENFIT

Fiscal Period: December	2021 (EUR)	2022 (EUR)	2023 (EUR)	2024 (EUR)	2025 (EUR)
France	-	20.2M	28.56M	67M	65.43M

See all geographic segments

Executive Committee: GENFIT

Manager	Title	Age	Since
Pascal Prigent CEO	Chief Executive Officer	58	2019-09-15
Thomas Baetz DFI	Director of Finance/CFO	52	2021-04-21
Pejvack Motlagh CTO	Chief Tech/Sci/R&D Officer	-	2025-11-26
Sakina Sayah-Jeanne CTO	Chief Tech/Sci/R&D Officer	-	2025-09-29
Meriam Kabbaj CTO	Chief Tech/Sci/R&D Officer	52	2022-11-30

See GENFIT governance

Composition of the Board of Directors: GENFIT

Director	Title	Age	Since
Jean-François Mouney CHM	Chairman	70	2017-06-15
Florence Séjourné BRD	Director/Board Member	54	1999-09-14
Anne-Hélène Monsellato BRD	Director/Board Member	58	2017-06-15
Catherine Larue BRD	Director/Board Member	70	2017-06-15
Katherine Kalin BRD	Director/Board Member	63	2020-07-06
Eric Baclet BRD	Director/Board Member	66	2020-07-06
Jean-François Tiné BRD	Director/Board Member	69	2021-03-03
Sandra Silvestri BRD	Director/Board Member	52	2023-05-31
Tristan Jacques Imbert BRD	Director/Board Member	60	2025-06-16

Composition of the Board of Directors

Shareholders: GENFIT

Name	Stocks	%	Valuation
IPSEN 7.955 %	3,985,239	7.955 %	67 M €
683 Capital Management LLC 5.873 %	2,942,242	5.873 %	50 M €
Biotech Avenir SAS 3.77 %	1,888,618	3.77 %	32 M €
Montpensier Arbevel SAS 0.2096 %	105,000	0.2096 %	2 M €
Pascal Prigent 0.0613 %	30,708	0.0613 %	517 954 €

List of GENFIT shareholders

Company details: GENFIT

Genfit SA

Parc Eurasante

59120, Loos

+33 3 20 16 40 00

http://www.genfit.com

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LONZA GROUP AG	-2.54%	-2.84%	-1.77%	+14.72%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+523.39%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+21.22%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+74.90%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+47.12%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+123.04%	16.5B
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+13.91%	+31.45%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.22%	13.77B
Average	-0.92%	+0.53%	+74.05%	+109.63%	30.55B
Weighted average by Cap.	-1.03%	+0.11%	+89.42%	+127.93%